Results 131 to 140 of about 11,142,973 (358)
The Use of Antibiotic Therapy as an Adjunct in Treatment of Bone and Joint Infections
Canadian Paediatric Society, Infectious Diseases and Immunization Committee
doaj +1 more source
Davide Dalu,1 Rosaria Iardino,2 Emanuela Vaccher,3 Angioletta Lasagna,4 Margherita Digaetano,5 Alberto Giovanni Leone,6 Lorenzo Ruggieri,1 Eva Massari,2 Eva Blondeaux,7 Andrea Gori,8,9 Cristina Mussini,10 Giuliano Rizzardini,9 Matteo Bassetti,11,12 ...
Dalu D +20 more
doaj
Protecting Health Care Workers from Infectious Diseases using Physical Proximity Networks (PPN) [PDF]
Asanka Rathnayaka +5 more
openalex +1 more source
ABSTRACT Objective Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is a progressive neuromuscular disorder with no approved treatments. Identifying reliable biomarkers is critical to monitor disease severity, activity, and progression. Interleukin‐6 (IL‐6) has been proposed as a candidate biomarker, but longitudinal validation is limited ...
Jonathan Pini +13 more
wiley +1 more source
R S, Heyderman, E, Larson
openaire +2 more sources
An Efficient AI Model for the Classification of Skin Lesions in Emerging Infectious Diseases [PDF]
Venkatesh Puppala
openalex +1 more source
Relapsing–Remitting Multiple Sclerosis Is Associated With a Dysbiotic Oral Microbiome
ABSTRACT Objective Multiple sclerosis (MS) is a chronic autoimmune disorder characterized by inflammation, demyelination, and neurological impairment. While the gut microbiota's role in MS is extensively studied, the association between the oral microbiota and MS remains underexplored, particularly in North American cohorts.
Sukirth M. Ganesan +12 more
wiley +1 more source
Should There Be Routine Testing for Human Immunodeficiency Virus Infection in Pregnancy?
Canadian Paediatric Society Infectious Diseases and Immunization Committee
doaj +1 more source
ABSTRACT Background There is growing recognition of the potential of plasma proteomics for Alzheimer's Disease (AD) risk assessment and disease characterization. However, differences between proteomics platforms introduce uncertainties regarding cross‐platform applicability.
Manyue Hu +9 more
wiley +1 more source

